Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Global generics pharmaceutical company with major revenue from US generics — notably complex products in inhalation/respiratory (albuterol and other inhalers), injectables and biosimilars — alongside a large India branded formulations franchise strong in cardiac, anti-diabetes and respiratory therapies. Also sells APIs and operates in emerging and developed markets ex-US; multiple FDA-inspected plants in India and abroad.
Among the top Indian pharma companies by revenue and a leading generic respiratory player in the US.
Lupin Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY MIDCAP SELECT, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Lupin Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 116.75 | 71.95 | 42.05 |
| Book value / share (₹) | 492.42 | 378.76 | 315.41 |
| Return on equity | 23.7% | 19.0% | 13.3% |
| Return on capital employed | 28.9% | 20.3% | 16.9% |
| Operating margin | 26.6% | 18.1% | 13.1% |
| Net margin | 19.2% | 14.6% | 9.7% |
| EBITDA | ₹8,816 Cr | ₹5,283 Cr | ₹3,811 Cr |
| Free cash flow | ₹5,491 Cr | ₹-1,252 Cr | ₹2,562 Cr |
| Total debt | ₹5,910 Cr | ₹5,077 Cr | ₹2,670 Cr |
| Debt to equity | 0.26 | 0.29 | 0.19 |
| Interest coverage | 17.1 | 13.9 | 8.4 |
| Current ratio | 1.90 | 1.87 | 1.58 |
| Shares outstanding | 45,72,00,000 | 45,66,00,000 | 45,57,00,000 |
Open the full income statement, balance sheet and cash flow for LUPIN →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.